| __timestamp | Geron Corporation | Johnson & Johnson |
|---|---|---|
| Wednesday, January 1, 2014 | 16758000 | 21954000000 |
| Thursday, January 1, 2015 | 17793000 | 21203000000 |
| Friday, January 1, 2016 | 18761000 | 19945000000 |
| Sunday, January 1, 2017 | 19287000 | 21420000000 |
| Monday, January 1, 2018 | 18707000 | 22540000000 |
| Tuesday, January 1, 2019 | 20893000 | 22178000000 |
| Wednesday, January 1, 2020 | 25678000 | 22084000000 |
| Friday, January 1, 2021 | 29665000 | 20118000000 |
| Saturday, January 1, 2022 | 43628000 | 19046000000 |
| Sunday, January 1, 2023 | 69135000 | 20112000000 |
| Monday, January 1, 2024 | 21969000000 |
In pursuit of knowledge
In the world of corporate finance, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Johnson & Johnson, a healthcare giant, and Geron Corporation, a biopharmaceutical company, offer a fascinating contrast in SG&A management from 2014 to 2023.
Johnson & Johnson consistently reported SG&A expenses around $20 billion annually, reflecting its vast operational scale. Despite fluctuations, their expenses remained relatively stable, showcasing effective cost management strategies. In contrast, Geron Corporation, with a smaller operational footprint, saw a dramatic increase in SG&A expenses, rising by over 300% from 2014 to 2023. This surge, from approximately $17 million to $69 million, highlights the challenges smaller companies face in scaling operations.
Understanding these trends provides valuable insights into how companies of different sizes manage operational costs, impacting their financial health and strategic growth.
SG&A Efficiency Analysis: Comparing Novo Nordisk A/S and Johnson & Johnson
Breaking Down SG&A Expenses: Johnson & Johnson vs MannKind Corporation
Johnson & Johnson and Amphastar Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Johnson & Johnson vs MiMedx Group, Inc.
Teva Pharmaceutical Industries Limited and Geron Corporation: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Summit Therapeutics Inc. and Geron Corporation
Comparing SG&A Expenses: Sarepta Therapeutics, Inc. vs Geron Corporation Trends and Insights
Who Optimizes SG&A Costs Better? Apellis Pharmaceuticals, Inc. or Geron Corporation
Comparing SG&A Expenses: PTC Therapeutics, Inc. vs Geron Corporation Trends and Insights
SG&A Efficiency Analysis: Comparing Bausch Health Companies Inc. and Geron Corporation
Comparing SG&A Expenses: Geron Corporation vs Taro Pharmaceutical Industries Ltd. Trends and Insights
Geron Corporation or Celldex Therapeutics, Inc.: Who Manages SG&A Costs Better?